A cost-benefit analysis of adult immunization programs across ten countries: Modeling the socioeconomic value of immunization for older populations compared to no vaccination.

Sulayman Chowdhury¹, Simon Brassel¹, Hania El Banhawi¹, Eleanor Bell^1,2, Margherita Neri^1,3, Lotte Steuten¹

¹Office of Health Economics, London, UK.

²U.K. Health Security Agency, London, UK.

³Verian Group, Brussels, Belgium.

PubMed PMC DOI PDF

Abstract

Globally aging demographics necessitate proactive public health interventions like adult immunization programs, but comprehensive estimates of their socioeconomic value are lacking or narrow in perspective, risking suboptimal decision-making. To estimate the socioeconomic value of adult immunization programs for influenza, pneumococcal disease, herpes zoster, and respiratory syncytial virus across…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.